Chemistry:RU-2309
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | 18-Methylmetribolone; 17α-Methyltetrahydrogestrinone; 17α-Methyl-THG; ∆9,11-17α,18-dimethyl-19-nortestosterone; 17α,18-Dimethylestr-4,9,11-trien-17β-ol-3-one |
| Drug class | Androgen; Anabolic steroid |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C20H26O2 |
| Molar mass | 298.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RU-2309, also known as 18-methylmetribolone, δ9,11-17α,18-dimethyl-19-nortestosterone, or 17α,18-dimethylestr-4,9,11-trien-17β-ol-3-one, is a 17α-alkylated androgen/anabolic steroid (AAS) of the 19-nortestosterone group which was never marketed.[1][2][3] It is the C18 methyl or C13β ethyl derivative of metribolone.[1][2] The compound is closely related to tetrahydrogestrinone (THG), which has the same chemical structure as RU-2309 except for possessing an ethyl group at the C17α position instead of a methyl group.[4] Hence, it could also be referred to as 17α-methyl-THG.[4] RU-2309 shows high affinity for the androgen, progesterone, and glucocorticoid receptors.[1][2][3]
See also
- List of androgens/anabolic steroids
References
- ↑ 1.0 1.1 1.2 "Steroid flexibility and receptor specificity". J. Steroid Biochem. 13 (1): 45–59. January 1980. doi:10.1016/0022-4731(80)90112-0. PMID 7382482.
- ↑ 2.0 2.1 2.2 "Unique steroid congeners for receptor studies". Cancer Res. 38 (11 Pt 2): 4186–98. November 1978. PMID 359134. http://cancerres.aacrjournals.org/content/38/11_Part_2/4186.short.
- ↑ 3.0 3.1 "A comparison of progestin and androgen receptor binding using the CoMFA technique". J. Comput. Aided Mol. Des. 6 (6): 569–81. December 1992. doi:10.1007/bf00126215. PMID 1291626. Bibcode: 1992JCAMD...6..569L.
- ↑ 4.0 4.1 U. s. Government Printing Office (29 May 2012). Food and Drugs, Part 1300 to End. Government Printing Office. pp. 6–. ISBN 978-0-16-090721-0. https://books.google.com/books?id=piqKQFmlay8C&pg=PA6.
| GR |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| PR |
| ||||||
|---|---|---|---|---|---|---|---|
| mPR (PAQR) |
| ||||||
 | 0.00  (0 votes) |
